SUNRISE-1 TAR-200 NMIBC Data – Journal of Clinical Oncology
TAR-200 Shows Promise as a Bladder-Sparing Option for BCG-Unresponsive Bladder cancer
New data suggests TAR-200 monotherapy may offer a superior risk-benefit profile compared to combination therapies or cetrelimab alone for patients with BCG-unresponsive CIS.
In a notable development for bladder cancer treatment, new findings indicate that TAR-200, an investigational intravesical gemcitabine releasing system, demonstrates a more favorable risk-benefit profile when used as a monotherapy compared to its combination with cetrelimab or cetrelimab alone in patients with BCG-unresponsive carcinoma in situ (CIS). This insight comes from recent data presented by the authors,highlighting TAR-200’s potential as a crucial bladder-sparing option.
Understanding the Latest Findings
The research, stemming from the phase IIb SunRISe-1 study, focused on patients with high-risk non-muscle-invasive bladder cancer (NMIBC) that did not respond to Bacillus Calmette-Guérin (BCG) therapy. The authors’ observation that TAR-200 monotherapy presented a more favorable risk-benefit profile is a key takeaway.This suggests that for many patients in this challenging treatment scenario, the simpler approach of TAR-200 alone might yield better outcomes with fewer associated risks then more complex combination regimens.
About TAR-200: A Novel Approach to Bladder Cancer Treatment
TAR-200 is an innovative intravesical therapy designed to deliver gemcitabine directly into the bladder over an extended period. Developed by Johnson & Johnson, this system aims to provide sustained local delivery of chemotherapy, maximizing its effect within the bladder while potentially minimizing systemic side effects.
The U.S. Food and Drug management (FDA) has recognized the potential of TAR-200 by granting it priority review for its new drug application (NDA). This review is specifically for its use in high-risk NMIBC with CIS, with or without papillary tumors, in patients who are unresponsive to BCG. This priority status is based on compelling data from cohort 2 of the SunRISe-1 trial, underscoring the significance of these findings.
Dr. Siamak Daneshmand, lead author and director of urologic oncology at the university of Southern California, expressed optimism about TAR-200’s impact.”With an 82.4% complete response rate and durable outcomes extending beyond 2 years, TAR-200 sets a new benchmark for bladder-sparing treatment in patients with BCG-unresponsive non-muscle-invasive bladder cancer,” he stated in correspondence with Urology Times®. He further emphasized that the SunRISe-1 trial positions TAR-200 as a “promising novel intravesical therapy for patients who are ineligible for or decline radical cystectomy.” This is particularly significant as radical cystectomy, the removal of the bladder, is a major surgery with significant implications for a patient’s quality of life.
The prospect of a highly effective, bladder-sparing treatment for BCG-unresponsive NMIBC is a beacon of hope for many patients. TAR-200’s ability to achieve high response rates and durable results without the need for more aggressive treatments like cystectomy could fundamentally change the treatment landscape for this condition.
REFERENCES
- Daneshmand S, heijden MSV, Jacob JM, et al. TAR-200 for Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer: Results from the phase IIb SunRISe-1 study.J Clin Oncol. 2025:101200JCO2501651. doi:10.1200/JCO-25-01651
- Johnson & Johnson receives U.S.FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer. News release. Johnson & Johnson. July 17, 2025. Accessed July 31, 2025. https://www.jnj.com/media-centre/press-releases/